News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News AZ sells migraine drug rights to Grunenthal for $300m AZ says migraine outside its strategic focus.
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
News Merck tries again in Alzheimer's with Teijin's tau antibody Target is implicated in a number of nervous system diseases.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
